104 results about "Ciclosporins" patented technology

The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.

The invention discloses primers for detecting polymorphism of CYP3A4, CYP3A5 and MDR1 genes with an ARMs-PCR (amplification refractory mutation system-polymerase chain reaction) method and a prepared kit. Primer sequences are shown in SEQ 1-SEQ 18. The primers can perform typing testing on CYP3A4, CYP3A5 and MDR1 genes of humans quickly and accurately through specific amplification after primer combination. Genetic typing or preparation of the typing kit can be performed according to the primers and the primers are used for detecting metabolic capacity of Chinese people for related drugs such as tacrolimus, cyclosporine A and the like, so that a reference basis can be provided for special doctors who determine optimal drug dosage and individual drug use, and drug use risks are reduced.

The invention relates to the medical technology field, and particularly relates to a solid self-microemulsion based on a spherical crystallization technique and a preparation method thereof. The solid self-microemulsion is characterized in that: with the use of the spherical crystallization technique, the solid self-microemulsifying micoparticles are prepared from poorly water soluble drugs in a liquid phase by one step. The solid self-microemulsion with the poorly water soluble drugs comprises the components, by weight: 0.1 to 1.5 g of the poorly water soluble drugs, 4.0 g of a polyoxyethylene hydrogenated castor oil, 2.0 g of capric caprylic triglyceride, 2.0 g of tpropylene glycol, 1.0 ml of ethanol, 4.0 ml of dichloromethane, 0.5 to 1.1 g of ethylcellulose (or Eudragit RS100, RL100), 0.05 g of PEG4000, and 0.5 g of colloidal silicon dioxide. The poorly water soluble drugs include cyclosporine A, fenofibrate, glimepiride, cilnidipine, isradipine, simvastatin, baicalein, neogambogic acid, puerarin, cyclovirobuxine D, silymarin and the like.

The invention relates to a Cyclosporin A rapidly releasing solid dosage forms in the medicine technical field and the preparation method. The components weight contents of the solid dosage forms of the invention are that: 0.5 to 5 percent CyA, 5 to 75 percent lipide, and 5 to 70 percent porosint. The invention adopts CyA as the medicine activity component which is dissolved in the heating meltdown lipid material and added with the porosint in order to be richly adsorbed, then solid combined powder is prepared to be further suppressed to tablet or filled into capsule. The moisture content of the invention permeates into the porosint as meeting with water so as to make the wrapped medicine-lipide dispersoid inflate by absorbing water, pile out the gape structure and the medicine can be released. The invention can amplify the solubility and stripping speed of CyA, is useful for the absorption of medicine, has good stability, prevents the uses of organic solvent and polyoxyethylene castor oil, has safe operation, reduces the poison as well as side effects of medicine and has immunological rejection resisting function.

The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.

The present invention provides a method for expanding PGC/PGCLC, including culturing PGC/PGCLC in the presence of a phosphodiesterase 4 (PDE4) inhibitor and/or cyclosporine A, further in the presence of forskolin, and a method for inducing oocytes from PGC/PGCLC, including culturing PGC/PGCLC in the presence of bone forming protein (BMP) and retinoic acid (RA).

The invention provides an in-situ gel containing cyclosporin micelles as a sustained release ophthalmic drug delivery system. The in-situ gel contains 0.01 wt% to 5 wt% of an aqueous ophthalmic formulation of cyclosporin present in the form of a micelle with the particle size of no greater than 20 nm.

The cyclosporin eye emulsion is prepared from the following components in percentage by mass: 0.01 to 0.05 percent of cyclosporin, 1.5 to 3 percent of collagen, 1.2 to 1.5 percent of castor oil, 1.8 to 2.5 percent of glycerol, 0.04 to 0.08 percent of anthocyanin, 0.8 to 1.2 percent of polysorbate 80 and the balance of double distilled water. The cyclosporin ophthalmic emulsion is prepared throughhigh-speed dispersion and shear emulsification, and collagen and anthocyanin in the emulsion are combined for use, so that the slow-release effect of the medicine can be effectively enhanced, and theresidual quantity of the medicine in corneas is increased.

The invention provides a method for detecting a cyclosporine pharmaceutical preparation, which comprises the following steps of: 1) treating the cyclosporine pharmaceutical preparation with a diluent to obtain a cyclosporine pharmaceutical preparation solution to be detected; and (2) detecting the cyclosporine pharmaceutical preparation solution to be detected obtained in the step (1) through using a gel chromatography exclusion method, wherein a chromatographic column adopted in the gel chromatography exclusion method detection is formed by connecting at least two water-soluble GPC chromatographic columns in series. The method can effectively separate povidone, OP-40 and polyoxyethylene hydrogenated castor oil, has the outstanding advantages of being good in stability, easy and convenient to operate, rapid, high in efficiency, good in sensitivity and the like, can achieve effective separation when the concentration of povidone, OP-40 and polyoxyethylene hydrogenated castor oil is low, and can provide a basis for further research on specific properties of any two or three of povidone, OP-40 and polyoxyethylene hydrogenated castor oil, such as cyclosporin eye drops.

The invention discloses application of cyclosporine A in preparation of a medicine for improving the embryo implantation rate of a patient suffering from repeated embryo implantation failure. In the prior art, the cyclosporine A is used as an immunosuppressor or a medicine for preventing miscarriage and preventing abortion, the application proposes that the cyclosporine A can improve the embryo planting rate for the first time, and particularly discloses improvement of the embryo planting rate of secondary embryo transplantation of the patient suffering from the repeated embryo implantation failure, and the research result is different from that in the prior art. Specifically, according to the technical scheme, clinical application of the cyclosporine A can be effectively guided, and side effects caused by improper medication are avoided.

Belonging to the field of chemical technologies, the invention relates to a preparation process for a cyclosporine A-pH sensitive nanoparticle, and more specifically relates to improvement of the preparation process of the cyclosporine A-pH sensitive nanoparticle. The preparation process for the cyclosporine A-pH sensitive nanoparticle is characterized by low cost and high synthesis rate, and the product has good intestinal absorption effect. The preparation process for the cyclosporine A-pH sensitive nanoparticle includes the steps of: weighing F68 and dissolving it in 125mL distilled water to serve as the water phase; dissolving 50mg of CyA and a proper amount of EudragitS100 in anhydrous ethanol to prepare an organic phase; injecting the organic phase into the water phase stirred at a speed of 400r.min with a No. 7 support marrow puncture needle quickly; and then conducting stirring continuously and transferring the mixture into 60DEG C water bath, and volatilizing the organic solvent completely, thus obtaining a CyA-NP colloidal solution.

The present invention relates to a composition comprising cyclosporine A (CsA) for use in the prevention of bronchiolitis obliterans syndrome (BOS) in a double lung transplanted patient, or for the treatment of BOS or for the prevention or delay of the progression of BOS in a double lung transplanted patient being diagnosed with BOS, wherein the composition is administered to said patient by inhalation of said composition in aerosolized form comprising a therapeutically effective dose of cyclosporine A.